NCT04838275Completed
IPF mHealth Exercise Study
A Mobile Health Exercise Prescription to Enhance Effectiveness of Antifibrotic Therapy in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Source: ClinicalTrials.gov · Last updated 24 Jul 2025
Brief summary (registry, in English)
Patients with idiopathic pulmonary fibrosis (IPF) who are stable on antifibrotic therapy at least 3 months will be randomized to complete a 12-week home exercise intervention using an mHealth platform, plus a pre- and post-intervention monitoring period (4 weeks each) and in-person study assessments.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 32 (actual)
- First submitted
- 5 Apr 2021
- Start date
- 1 May 2021
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- University of Washington
- Diseases
- Idiopathic pulmonary fibrosis
- NCT number
- NCT04838275
What you commit to
- Study type: Interventional
- Participants enrolled: 32
- From 1 May 2021 to the primary completion date, 31 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Expected to receive a lung transplant within 1 year from randomization or, for patients at sites in the United States, on a lung transplant waiting list at randomization
- Ongoing IPF treatments including investigational therapy, immunosuppresents (other than prednisone 20 mg daily and below) and cytokine modulating agents
- Participation in a supervised exercise program including pulmonary rehab within the previous 12 months
- History of unstable or deteriorating cardiac or pulmonary disease (other than IPF) within the previous 6 months
Other illness
- Known explanation for interstitial lung disease
- History of asthma or chronic obstructive pulmonary disease
- Active infection
- Major orthopedic, psychiatric, neurological, or other conditions that would impair performance of the study exercise outcomes
Other
- Forced expiratory volume in one second (FEV1)/FVC ratio \<0.7 after administration of bronchodilator at screening
- Require \>5LPM supplemental O2 at rest
- Currently pregnant
Who the study is looking for
- Age 40-80 yrs at randomization
- Diagnosis of idiopathic pulmonary fibrosis (IPF), consistent with the ATS 2018 Guidelines
- Percent Forced Vital Capacity (%FVC) ≥50%
- Percent Carbon Monoxide Diffusing Capacity (%DLCO) ≥30%
- Willing and able to participate in an exercise regimen
- Ambulatory without the use of an assistive device
- Stable on antifibrotic therapy (pirfenidone or nintedanib) at least 3 months
- No changes in other medication for at least 4 wks before enrollment
- Must be able to read, write, and verbally communicate in English
Age in the registry: 40 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Washington Coordinator of this site? Confirm its status | Seattle | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.